CTKB · XBRL financial data

Cytek Biosciences financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CTKB's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	127,950	164,036	193,015	—	—
Revenue from contracts with customers	127,950	164,036	193,015	200,453	201,493
Cost of goods and services sold	48,806	63,062	83,589	89,347	97,033
Gross profit	79,144	100,974	109,426	111,106	104,460
Research and development	24,442	34,858	44,151	39,402	36,468
General and administrative	20,835	34,690	43,972	43,113	58,936
Total operating expenses	69,987	102,778	137,271	131,629	144,844
Operating income (loss)	9,157	(1,804)	(27,845)	(20,523)	(40,384)
Interest income	49	4,619	6,413	5,121	2,216
Interest expense	1,741	2,573	2,071	(5,239)	474
Other income (expense)	(1,527)	1,018	7,794	4,463	8,801
Income tax expense (benefit)	2,911	(1,224)	(3,561)	320	36,698
Net income (loss)	3,027	2,484	(12,148)	(6,020)	(66,539)
Earnings per share, basic USD per share	0.00	0.02	(0.09)	—	—
Earnings per share, diluted USD per share	0.00	0.02	(0.09)	—	—
Weighted average shares, basic thousands of shares	76,742	134,511	135,283	130,611	127,746
Weighted average shares, diluted thousands of shares	81,543	138,562	135,283	130,611	127,746

Fiscal years (CTKB's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	364,618	296,601	167,299	98,716	90,853
Accounts receivable	29,760	48,864	55,928	60,588	62,509
Inventory	32,171	48,154	60,877	43,893	48,428
Prepaid and other current assets	5,184	12,954	12,514	14,075	19,530
Total current assets	431,733	454,020	392,060	396,446	391,996
Property and equipment, net	5,851	13,682	18,405	17,962	18,009
Right-of-use asset	0	13,883	10,853	10,168	11,315
Goodwill	10,144	10,144	16,183	16,663	16,697
Total assets	463,305	519,476	494,457	499,500	461,542
Accrued liabilities	15,251	21,126	20,035	21,443	23,417
Total current liabilities	33,181	49,040	56,226	67,663	77,804
Lease liability, non-current	0	12,312	9,479	7,552	14,042
Total liabilities	57,920	93,930	101,393	103,763	119,803
Accumulated deficit	(19,606)	(17,030)	(29,178)	(35,199)	(101,738)
Total stockholders' equity	405,385	425,546	393,064	395,737	341,739
Total liabilities and equity	463,305	519,476	494,457	499,500	461,542
Common shares outstanding (cover page) thousands of shares	134,077	135,431	130,824	128,097	128,550

Fiscal years (CTKB's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	3,027	2,484	(12,148)	(6,020)	(66,539)
Stock-based compensation	6,586	16,595	22,048	26,848	24,585
Depreciation and amortization	1,242	2,492	6,048	7,212	7,579
Net cash from operating activities	4,630	(12,231)	5,281	25,379	(4,686)
Purchases of property and equipment	4,364	9,748	4,648	3,525	4,084
Net cash from investing activities	(20,993)	(55,909)	(93,894)	(82,974)	10,117
Share repurchases	0	0	44,151	21,611	15,074
Net cash from financing activities	213,559	5,513	(41,812)	(15,822)	(13,432)
Net change in cash	198,499	(65,118)	(131,870)	(68,885)	(7,892)

SIC 3826 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3826 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Cytek Biosciences	73,846	48,140	1,367*	130.0M	—	Q2 FY26 10-QJun 30, 2026
Crawford United	1,923	not reported	5,706*	not reported	—	Q3 FY25 10-QSep 30, 2025
Senseonics Holdings	44,753	14,483	(30,138)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Pacific Biosciences of California	61,003	39,007	(35,583)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Mesa Laboratories	30,695	60,138	14,736	5.6M	—	Q1 FY27 10-QJun 30, 2026
Allient	42,088	153,770	13,954*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Quantum-Si	23,653	344	(18,444)*	not reported	6.1 quarters	Q2 FY26 10-QJun 30, 2026
Alamar Biosciences	121,532	33,545	not reported	69.5M	—	Q3 FY26 10-QSep 30, 2026
Frequency Electronics	61,407	23,451	2,622	11.3M	—	Q1 FY27 10-QJul 31, 2026

Not investment advice. Not affiliated with the U.S. SEC.